ArcticZymes Technologies ASA

AZT

NO0010014632

Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 03:55:34 2024-05-22 am EDT			5-day change	1st Jan Change
24.85 ^NOK	+0.81%		+5.07%	-40.83%

May. 13	ArcticZymes Technologies ASA Announces Board Resignations	CI
May. 08	ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Arcticzymes Technologies Asa Provides Earnings Guidance for the Year 2021

October 28, 2021 at 02:30 am EDT

ArcticZymes Technologies ASA provided earnings guidance for the year 2021. For the period, the company expects annual sales revenue target of NOK 120 million.

Latest news about ArcticZymes Technologies ASA

ArcticZymes Technologies ASA Announces Board Resignations	May. 13	CI
ArcticZymes Technologies ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Transcript : ArcticZymes Technologies ASA, Q1 2024 Earnings Call, May 08, 2024	May. 08
Norway's ArcticZymes Teams Up With Austrian Group for Bionanoparticles Research Project	Apr. 09	MT
ArcticZymes Technologies ASA Initiates Joint Research Project with Austrian Centre of Industrial Biotechnology	Apr. 09	CI
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member	Apr. 02	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 01	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 01	CI
Transcript : ArcticZymes Technologies ASA, Q4 2023 Earnings Call, Feb 01, 2024	Feb. 01
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq	Jan. 30	CI
Norway’s ArcticZymes Technologies Manufactures GMP-grade Enzyme	Jan. 30	MT
ArcticZymes Technologies ASA Launches T7 RNA Polymerase	Dec. 21	CI
ArcticZymes Technologies ASA Enters into an Agreement with Biomatter	Dec. 19	CI
ArcticZymes Technologies ASA Announces Partnership with Biomatter	Dec. 19	CI
ArcticZymes Technologies ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Transcript : ArcticZymes Technologies ASA, Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
ArcticZymes Technologies' Wins US FDA's Filing Type 2 Status for Enzyme	23-09-21	MT
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA	23-09-21	CI
ArcticZymes Technologies ASA(OB:AZT) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : ArcticZymes Technologies ASA, Q2 2023 Earnings Call, Aug 17, 2023	23-08-17
ArcticZymes Technologies ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
ArcticZymes Technologies ASA Launches Taq?? DNA Polymerase	23-08-09	CI
ArcticZymes Technologies Appoints New CEO	23-07-17	MT
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023	23-07-17	CI
ArcticZymes Technologies Files DMF for SAN HQ GMP	23-06-29	CI

Chart ArcticZymes Technologies ASA

Duration

Period

More charts

Arcticzymes Technologies ASA is a Norway-based holding company providing support functions to the ArcticZymes AS subsidiary including distribution, administration, finance, Information Technology (IT) and quality assurance. As a life science company, Arcticzymes Technologies ASA is focused on the development, manufacturing, and commercialization of novel and high-quality recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. Some of the key features of the Companyâs enzymes include cold activeness and salt tolerance. The Companyâs divided into two operating segments; Enzymes and Corporate. Arcticzymes established logistic hubs in the United States and the Netherlands to serve its customers more efficiently.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ArcticZymes Technologies ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

24.65 NOK

Average target price

27.5 NOK

Spread / Average Target

+11.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCTICZYMES TECHNOLOGIES ASA	-40.83%	118M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.96%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research